Table 1.
Results from clinical trials using TCR-T cells.
| Taregt Ag. of TCR | Cell Dose (× 109) | Target Disease Pt.No. (n) | Preconditioning | AEs (Grade) | Clinical Responses | Ref. |
|---|---|---|---|---|---|---|
| MART-1 | 1.0–86 | melanoma | Cy + Flud | No | PR 2/17 | [37] |
| (n = 17) | ||||||
| MART-1* | 1.5–107 | melanoma (20) | Cy + Flud | skin, eye (G2) | PR 6/20 | [27] |
| gp100** | 1.8–110 | melanoma (16) | ear (G3) | CR 1/16,PR 2/16 | ||
| (n = 36) | ||||||
| p53**/gp100** | 0.5–27.7 | breast ca. (4) | Cy + Flud | N/A | PR 1/9 | [38] |
| melanoma (2) | ||||||
| esoph.ca. (1) | ||||||
| others (2) | ||||||
| CEA* | 0.2–0.4 | colorectal ca. | Cy + Flud | colitis (G3) | PR 1/3 | [28] |
| (n = 3) | CEA decreased 3/3 | |||||
| NY-ESO-1* | 1.6–130 | melanoma (11) | Cy + Flud | No | CR 2/11, PR 3/11 | [29] |
| synovial cell ca.(6) | PR 4/6 | |||||
| (n = 17) | ||||||
| MAGE-A3* | 29–79 | melanoma (7) | Cy + Flud | mental disturbance (G4) | Tumor regression | [25] |
| synovial cell ca.(1) | 2/3 died of necrotizing | 5/9 | ||||
| esoph.ca. (1) | leukoencephalopathy | |||||
| (n = 9) | (on-target AE) | |||||
| MAGE-A3* | 5.3 & 2.4 | melonoma (1) | Cy | 2/2 died of cardiogenic | NE | [26] |
| myeloma (1) | melphalan + autoSCT | shock | ||||
| (n = 2) | (off-target AE) | |||||
Abbreviations: Ag: antigen; AE: adverse events; Ref.: reference; Cy: cyclophosphamide; Flud: fludarabine; PR: partial response; CR: complete remission by response evaluation criteria in solid tumors (RECIST) *: affinity-increased TCR; **: mouse-derived high-avidity TCR; breast ca.: breast cancer; esoph.ca.: esophageal cancer; synovial cell ca.: synovial cell carcinoma; N/A; not available; N/E: not evaluable; autoSCT: autologous stem cell transplant.